Citations

Showing 10 of 108083 citations.

Verteporfin-loaded microparticles for radiosensitization of preclinical lung and breast metastatic spine cancer
Suárez-Meade, Paola , Roberts, McKinley, Tzeng, Stephany Y. , Norton, Emily S. , Gokaslan, Ziya L. , Anastasiadis, Panos Z. , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Guerrero-Cazares, Hugo , Tzeng, Stephany Y , Akinduro, Oluwaseun O. , Roberts, Mckinley, Sarabia-Estrada, Rachel , Schiapparelli, Paula , Green, Jordan J.

Mayo Clinic

Journal of Neurosurgery: Spine | January 13, 2023 | Volume: 38 | Issue: 4 | Pages: 481-493

10.3171/2022.11.spine22867 | PMID 36585863 Get It

OBJECTIVE The vertebral column is the most common site for skeletal metastasis, often leading to debilitating pain and weakness. Metastatic cancer has unique genetic drivers that potentiate tumorigenicity. There is an unmet need for novel targeted therapy in patients with spinal metastatic disease. METHODS The authors assessed the effect of verteporfin-induced yes-associated protein (YAP) inhibition on spine metastatic cell tumorigenicity and radiation sensitivity in vitro. Animal studies used a subcutaneous xenograft mouse model to assess the use of systemic intraperitoneal verteporfin (IP-VP) and intratumoral verteporfin microparticles (IT-VP) to inhibit the tumorigenicity of lung and breast spinal metastatic tumors from primary patient-derived tissue. RESULTS Verteporfin led to a dose-dependent decrease in migration, clonogenicity, and cell viability via inhibition of YAP and downstream effectors cyclin D1, CTGF, TOP2A, ANDRD1, MCL-1, FOSL2, KIF14, and KIF23. This was confirmed with knockdown of YAP. Verteporfin has an additive response when combined with radiation, and knockdown of YAP rendered cells more sensitive to radiation. The addition of verteporfin to YAP knockdown cells did not significantly alter migration, clonogenicity, or cell viability. IP-VP and IT-VP led to diminished tumor growth (p < 0.0001), especially when combined with radiation (p < 0.0001). Tissue analysis revealed diminished expression of YAP (p < 0.0001), MCL-1 (p < 0.0001), and Ki-67 (p < 0.0001) in tissue from verteporfin-treated tumors compared with vehicle-treated tumors. CONCLUSIONS This is the first study to demonstrate that verteporfin-mediated inhibition of YAP leads to diminished tumorigenicity in lung and breast spinal metastatic cancer cells. Targeting of YAP with verteporfin offers promising results that could be translated to human clinical trials.
Left-sided valvular heart disease and retinopathy in a 38-year-old woman with attenuated mucopolysaccharidosis: a case report
Asumda, Faizal Z., Kraker, Jessica A. , Thomas, Sarah , Maleszewski, Joseph J. , Stone, Edwin M. , Lanpher, Brendan C. , Schimmenti, Lisa A. , Thomas, Sarah C, Maleszewski, Joseph, Schimmenti, Lisa A , Thomas, Sarah C.

Mayo Clinic

Therapeutic Advances in Rare Disease | January 13, 2023 | Volume: 4 | Issue: No issue available | Pages: No page available

10.1177/26330040221145945 | PMID 37181073 Get It

Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders caused by deficient levels and/or activity of glycosaminoglycan (GAG)-degradative enzymes. MPS are characterized by accumulation of the mucopolysaccharides heparan sulfate, dermatan sulfate, keratan sulfate, or chondroitin sulfate in tissues. We report the case of a 38-year-old woman with a history of joint restriction and retinitis pigmentosa who developed bivalvular heart failure requiring surgery. It was not until pathological examination of surgically excised valvular tissue that a diagnosis of MPS I was made. Her musculoskeletal and ophthalmologic symptoms, when placed in the context of MPS I, painted the diagnostic picture of a genetic syndrome that was overlooked until a diagnosis was made in late middle age.
Inflammatory induration in hidradenitis suppurativa and application to severity assessment
Bellefeuille, Gretchen, Paiewonsky, Briana , Khalid, Bisma, Freese, Rebecca , Kirby, Joslyn S. , Goldfarb, Noah , Goldfarb, Noah , Lowes, Michelle A , Alavi, Afsáneh

Mayo Clinic

British Journal of Dermatology | January 12, 2023 | Volume: 188 | Issue: 2 | Pages: 309-310

10.1093/bjd/ljac076 | PMID 36634097 Get It

Skin thickness, as known as inflammatory induration, is a component in several HS grading instruments including the HASI and HASI-R. This study sought to evaluate how thickest lesion measurement (mm) corresponds to HS severity. This study demonstrates that inflammatory induration has moderate association with HS severity, thickest lesion measurement (mm) demonstrates known-validity across Hurley stages, and cut-offs for thickest lesion measurement (mm) were determined for inflammatory induration grading for the purpose of HASI-R training.
Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium
Verna, Elizabeth C. , Phipps, Meaghan , Halazun, Karim J. , Markovic, Daniela , Haydel, Brandy , Ruiz, Richard , Klintmalm, Göran B. , Lee, David D. , Taner, C. Burcin , Tevar, Amit D. , Humar, Abhinav , Chapman, William C. , Vachharajani, Neeta , Aucejo, Federico , Nguyen, Mindie H. , Nydam, Trevor L. , Markmann, James F. , Mobley, Constance M. , Ghobrial, Rafik M. , Langnas, Alan N. , Carney, Carol A., Berumen, Jennifer , Sudan, Debra L. , Hong, Johnny C. , Rana, Abbas , Jones, Christopher M. , Fishbein, Thomas , Busuttil, Ronald W. , Klintmalm, Goran , Lee, David D , Taner, Burcin , Humar, Abhinav , Melcher, Marc L , Mobley, Constance , Schnickel, Gabriel T , Halazun, Karim J , Chapman, William C , Sudan, Debra L , Florman, Sander , Hoteit, Maarouf , Melcher, Marc L. , Agopian, Vatche G.

Mayo Clinic

Liver Transplantation | January 12, 2023 | Volume: 29 | Issue: 1 | Pages: 34-47

10.1097/lvt.0000000000000007 | PMID 36630156 Get It

NAFLD will soon be the most common indication for liver transplantation (LT). In NAFLD, HCC may occur at earlier stages of fibrosis and present with more advanced tumor stage, raising concern for aggressive disease. Thus, adult LT recipients with HCC from 20 US centers transplanted between 2002 and 2013 were analyzed to determine whether NAFLD impacts recurrence-free post-LT survival. Five hundred and thirty-eight (10.8%) of 4981 total patients had NAFLD. Patients with NAFLD were significantly older (63 vs. 58, p<0.001), had higher body mass index (30.5 vs. 27.4, p<0.001), and were more likely to have diabetes (57.3% vs. 28.8%, p<0.001). Patients with NAFLD were less likely to receive pre-LT locoregional therapy (63.6% vs. 72.9%, p<0.001), had higher median lab MELD (15 vs. 13, p<0.001) and neutrophil-lymphocyte ratio (3.8 vs. 2.9, p<0.001), and were more likely to have their maximum pre-LT alpha fetoprotein at time of LT (44.1% vs. 36.1%, p<0.001). NAFLD patients were more likely to have an incidental HCC on explant (19.4% vs. 10.4%, p<0.001); however, explant characteristics including tumor differentiation and vascular invasion were not different between groups. Comparing NAFLD and non-NAFLD patients, the 1, 3, and 5-year cumulative incidence of recurrence (3.1%, 9.1%, 11.5% vs. 4.9%, 10.1%, 12.6%, p=0.36) and recurrence-free survival rates (87%, 76%, and 67% vs. 87%, 75%, and 67%, p=0.97) were not different. In competing risks analysis, NAFLD did not significantly impact recurrence in univariable (HR: 0.88, p=0.36) nor in adjusted analysis (HR: 0.91, p=0.49). With NAFLD among the most common causes of HCC and poised to become the leading indication for LT, a better understanding of disease-specific models to predict recurrence is needed. In this NAFLD cohort, incidental HCCs were common, raising concerns about early detection. However, despite less locoregional therapy and high neutrophil-lymphocyte ratio, explant tumor characteristics and post-transplant recurrence-free survival were not different compared to non-NAFLD patients.
Review of systemic and syndromic complications of cannabis use: A review
Fermo, Olga , Fermo, Olga , Shah, Jay

Mayo Clinic

Medicine | January 12, 2023 | Volume: 101 | Issue: 49 | Pages: e32111

10.1097/md.0000000000032111 | PMID 36626471 Get It

Purpose of review: Prescribed and non-prescribed cannabis use is common. Providers in specialties treating chronic pain – primary care, pain management, and neurology–will be coming across medical cannabis as a treatment for chronic pain, regardless of whether they are prescribers. It is important to be aware of the systemic and syndromic complications of acute and chronic cannabis use in the differential diagnosis of cardiac, cardiovascular, cerebrovascular, gastrointestinal, and psychiatric disorders. Recent Findings: Medical cannabis is legal in 36 states. Studies have shown several potentially serious adverse effects associated with cannabis use. Summary: Cannabis use has the potential to cause several complications that can be easily overlooked without a preexisting high index of suspicion.
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Senefeld, Jonathon W. , Zani, Matteo , Gorman, Ellen K. , Joyner, Michael J. , Joyner, Michael J , Senefeld, Jonathon W , Franchini, Massimo , Mengoli, Carlo , Cruciani, Mario , Focosi, Daniele , Casadevall, Arturo

Mayo Clinic

JAMA Network Open | January 12, 2023 | Volume: 6 | Issue: 1 | Pages: e2250647

10.1001/jamanetworkopen.2022.50647 | PMID 36633846 Get It

ImportancePatients who are immunocompromised have increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) because they less frequently mount antibody responses to vaccines. Although neutralizing anti-spike monoclonal-antibody treatment has been widely used to treat COVID-19, evolutions of SARS-CoV-2 have been associated with monoclonal antibody-resistant SARS-CoV-2 variants and greater virulence and transmissibility of SARS-CoV-2. Thus, the therapeutic use of COVID-19 convalescent plasma has increased on the presumption that such plasma contains potentially therapeutic antibodies to SARS-CoV-2 that can be passively transferred to the plasma recipient.ObjectiveTo assess the growing number of reports of clinical experiences of patients with COVID-19 who are immunocompromised and treated with specific neutralizing antibodies via COVID-19 convalescent plasma transfusion.Data SourcesOn August 12, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma use in patients who are immunocompromised.Study SelectionRandomized clinical trials, matched cohort studies, and case report or series on COVID-19 convalescent plasma use in patients who are immunocompromised were included. The electronic search yielded 462 unique records, of which 199 were considered for full-text screening.Data Extraction and SynthesisThe study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were extracted by 3 independent reviewers in duplicate and pooled.Main Outcomes and MeauresThe prespecified end point was all-cause mortality after COVID-19 convalescent plasma transfusion; exploratory subgroup analyses were performed based on putative factors associated with the potential mortality benefit of convalescent plasma.ResultsThis systematic review and meta-analysis included 3 randomized clinical trials enrolling 1487 participants and 5 controlled studies. Additionally, 125 case series or reports enrolling 265 participants and 13 uncontrolled large case series enrolling 358 participants were included. Separate meta-analyses, using models both stratified and pooled by study type (ie, randomized clinical trials and matched cohort studies), demonstrated that transfusion of COVID-19 convalescent plasma was associated with a decrease in mortality compared with the control cohort for the amalgam of both randomized clinical trials and matched cohort studies (risk ratio [RR], 0.63 [95% CI, 0.50-0.79]).Conclusions and RelevanceThese findings suggest that transfusion of COVID-19 convalescent plasma is associated with mortality benefit for patients who are immunocompromised and have COVID-19.
Social Determinants of Health: A Need for Evidence-Based Guidelines on How to Capture Data on Underserved Patients
Almodallal, Yahya , Batheja, Mashal, Martin, Nicole Alice , Jatoi, Aminah , Martin, Nicole, Ridgeway, Jennifer, Sia, Irene G. , Tran, Nguyen Hoang Khoi , Martin, Nicole, Le‐Rademacher, Jennifer , Ridgeway, Jennifer L.

Mayo Clinic

No container title available | January 12, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2451501/v1 | PMID 36711509 Get It

Abstract Background. Social determinants of health lead to better cancer care. This multi-site, single-institution study sought to capture data on social determinants of health data in Asian Americans with hepatocellular carcinoma; this group constitutes 60% of patients with this malignancy and are often undertreated or not treated at all. Methods. This study took advantage of an institutional initiative designed to capture and integrate social determinants of health data into the electronic medical record for all patients. Medical records of Asian Americans with hepatocellular cancer were reviewed to acquire data on housing instability, lack of transportation, financial concerns, and social isolation; a score of 1 indicated poor social determinants of health. Results. Of 112 adult Asian American patients with hepatocellular cancer, 22 (20%) were Southeast Asian, and 74 (67%) described English proficiency. A score of 1 (highest risk) was observed in 1 patient (0.9%) for housing instability; 1 (0.9%) lack of transportation; no patient for financial hardship; and 1 (0.9%) for social isolation. However – and importantly -- total noncompletion per domain (no question answered within that domain) was observed in 90 patients (80%) for housing instability; 90 (80%) for lack of transportation; 92 (82%) for financial hardship; and 90 (80%) for social isolation. Of note, institution-wide benchmark total noncompletion rates were 0.3%, 0.3%, 47%, and 39% for these respective domains. Conclusion. High total noncompletion rates make social determinants of health data challenging to interpret and underscore the need for evidence-based guidelines on how best to capture such data in underserved patients.
S-22-4: GENOME WIDE ASSOCIATION STUDY OF FIBROMUSCULAR DYSPLASIA REVEALS MECHANISTIC LINKS WITH BLOOD PRESSURE REGULATION AND OTHER VASCULAR DISEASES
Sayed, Ines Sadoug, Vikkula, Mikka, Januszewicz, Andrzej , Kullo, Iftikhar, Jeunemaı̂tre, Xavier , Naji, Nabila Bouatia, Georges, Adrien , Yang, Min , Berrandou, Takiy-Eddine , Liu, Lu , Dikilitas, Ozan , Azizi, Michel , Persu, Alexandre , Kovacic, Jason C. , Ganesh, Santhi K.

Mayo Clinic

Journal of Hypertension | January 12, 2023 | Volume: 41 | Issue: Suppl 1 | Pages: e54

10.1097/01.hjh.0000913240.04466.fb Get It

Introduction: Fibromuscular dysplasia (FMD) is a non-atherosclerotic arteriopathy of unknown etiology, afflicting mostly middle-aged women. It is characterized by stenotic lesions of the vascular wall in middle-size arteries, sometimes associated with dissection, aneurysm or tortuosity. Renovascular hypertension is a major presentation of FMD and 50–85% of FMD patients are hypertensive. Methods & Results: We report results from the first genome-wide association meta-analysis of six studies including 1556 FMD cases and 7100 controls. We identified four robustly associated loci (PHACTR1, LRP1, ATP2B1, and LIMA1). Using colocalization and transcriptome-wide association analysis with arterial expression datasets, we found PHACTR1, LRP1 and ATP2B1 as target genes at FMD loci and identified one additional locus (SLC24A3). We analysed chromatin accessibility in artery-derived primary cells and found that FMD associated variants were located in arterial specific regulatory elements active in smooth muscle cells. Target genes were broadly involved in mechanisms related to actin cytoskeleton and intracellular calcium homeostasis, central to vascular contraction. All FMD loci were also associated to at least one blood pressure trait. Colocalization analysis supported the same genetic variants to cause association to FMD and systolic blood pressure at PHACTR1, ATP2B1 and LIMA1 loci, and for FMD and pulse pressure at PHACTR1, LRP1 and ATP2B1 loci. Using genome-wide genetic correlation, we found a significant association between FMD and blood pressure. Mendelian Randomization analysis supported genetically determined systolic blood pressure to significantly increase the risk of FMD. However, we confirmed using adjusted and stratified analyses that hypertension status alone was not driving the association with FMD at top loci. We also report an important genetic overlap of FMD with migraine, intracranial aneurysm, coronary artery disease and myocardial infarction. Conclusion: Our study confirms FMD as a polygenic disease following a complex genetic mode of inheritance. We find that FMD shares an important part of its genetic basis with blood pressure regulation, involving in particular several genes related to intracellular calcium homeostasis and vascular smooth muscle contraction. These results are consistent with previous studies showing systemic alterations in vascular contraction in FMD patients, even outside of affected arterial beds. While the mechanisms through which FMD may cause renovascular hypertension are well known, further studies will be required to determine how alterations in vascular contraction may lead to the arterial remodeling observed in FMD.
Reverse of left ventricular remodeling in heart failure patients with left bundle branch area pacing: Systematic review and meta‐analysis
Siranart, Noppachai , Chokesuwattanaskul, Ronpichai , Prasitlumkum, Narut , Huntrakul, Anurut , Phanthong, Tanattida, Sowalertrat, Walit , Navaravong, Leenhapong , Cheungpasitporn, Wisit , Jongnarangsin, Krit, Cheungpasitporn, Wisit , Chokesuwattanaskul, Ronpichai , Navaravong, Leenhapong , Prasitlumkum, Narut , Siranart, Noppachai

Mayo Clinic

Pacing and Clinical Electrophysiology | January 12, 2023 | Volume: 46 | Issue: 6 | Pages: 459-466

10.1111/pace.14661 | PMID 36633357 Get It

AbstractBackgroundLeft bundle branch area pacing (LBBAP) has recently become a promising option for the near‐natural restoration of electrical activation. However, the clinical relevance of therapeutic effects in individuals with heart failure with reduced ejection fraction (HFrEF) and dyssynchrony remains unknown.MethodsMEDLINE, EMBASE, and Cochrane databases were searched from inception until June 2022. Data from each study was combined using a random‐effects model, the generic inverse variance method of DerSimonian and Laird, to calculate standard mean differences and pooled incidence ratio, with 95% confidence intervals (CIs).ResultsA total of 772 HFrEF patients were analyzed from 15 observational studies per protocol. The success rate of LBBAP implantation was 94.8% (95% CI 89.9–99.6, I2 = 79.4%), which was strongly correlated with shortening QRS duration after LBBAP implantation, with a mean difference of −48.10 ms (95% CI −60.16 to −36.05, I2 = 96.7%). Over a period of 6–12 months of follow‐up, pacing parameters were stable over time. There were significant improvements in left ventricular ejection fraction (LVEF), left ventricular end‐systolic volume (LVESV), left ventricular end‐diastolic diameter (LVEDD), and left ventricular end‐diastolic volume (LVEDV) with mean difference of 16.38% (95% CI 13.13–19.63, I2 = 90.2%), −46.23 ml (95% CI −63.17 to −29.29, I2 = 86.82%), −7.21 mm (95% CI −9.71 to −4.71, I2 = 84.6%), and −44.52 ml (95% CI −64.40 to −24.64, I2 = 85.9%), respectively.ConclusionsLBBAP was associated with improvements in both cardiac function and electrical synchrony. The benefits of LBBAP in individuals with HFrEF and dyssynchrony should be further validated by randomized studies.